División de Salud Pública y Medicina Familiar, Escuela de Medicina Pontificia Universidad Católica de Chile, Marcoleta 434, Santiago 8330073, Chile.
Infect Agent Cancer. 2011 Nov 16;6(1):21. doi: 10.1186/1750-9378-6-21.
The need to review cervical cancer prevention strategies has been triggered by the availability of new prevention tools linked to human papillomavirus (HPV): vaccines and screening tests. To consider these innovations, information on HPV type distribution and natural history is necessary. This is a five-year follow-up study of gynecological high-risk (HR) HPV infection among a Chilean population-based cohort of women.
A population-based random sample of 969 women from Santiago, Chile aged 17 years or older was enrolled in 2001 and revisited in 2006. At both visits they answered a survey on demographics and sexual history and provided a cervical sample for HPV DNA detection (GP5+/6+ primer-mediated PCR and Reverse line blot genotyping). Follow-up was completed by 576 (59.4%) women; 45 (4.6%) refused participation; most losses to follow-up were women who were unreachable, no longer eligible or had missing samples. HR-HPV prevalence increased by 43%. Incidence was highest in women < 20 years of age (19.4%) and lowest in women > 70 (0%); it was three times higher among women HR-HPV positive versus HPV negative at baseline (25.5% and 8.3%; OR 3.8, 95% CI 1.8-8.0). Type-specific persistence was 35.3%; it increased with age, from 0% in women < 30 years of age to 100% in women > 70. An enrollment Pap result ASCUS or worse was the only risk factor for being HR-HPV positive at both visits.
HR-HPV prevalence increased in the study population. All HR-HPV infections in women < 30 years old cleared, supporting the current recommendation of HR-HPV screening for women > 30 years.
由于人类乳头瘤病毒(HPV)相关新预防工具(疫苗和筛查试验)的出现,需要对宫颈癌预防策略进行审查。考虑到这些创新,有必要了解 HPV 型别分布和自然史的信息。这是对智利人群为基础的妇女队列中妇科高危(HR)HPV 感染进行的为期五年的随访研究。
2001 年招募了智利圣地亚哥的一个年龄在 17 岁及以上的人群为基础的随机样本 969 名妇女,2006 年对她们进行了随访。两次就诊时,她们都回答了关于人口统计学和性史的调查问卷,并提供了宫颈样本进行 HPV DNA 检测(GP5+/6+引物介导 PCR 和反向线印迹基因分型)。576 名(59.4%)妇女完成了随访;45 名(4.6%)拒绝参与;大多数失访是因为无法联系、不再符合条件或样本缺失的妇女。HR-HPV 的患病率增加了 43%。发病率在<20 岁的妇女中最高(19.4%),在>70 岁的妇女中最低(0%);在基线时 HR-HPV 阳性的妇女中,发病率是 HR-HPV 阴性的妇女的三倍(25.5%和 8.3%;OR 3.8,95%CI 1.8-8.0)。特定型别持续性为 35.3%;它随着年龄的增长而增加,从<30 岁的妇女中的 0%增加到>70 岁的妇女中的 100%。初次就诊时巴氏结果 ASCUS 或更差是两次就诊时 HR-HPV 阳性的唯一危险因素。
研究人群中 HR-HPV 的患病率增加。所有<30 岁的妇女的 HR-HPV 感染都清除了,这支持了目前对>30 岁妇女进行 HR-HPV 筛查的建议。